High Hopes, Hard Reality: Merck and Gilead's Lung Cancer Combo Trial Falters

RAHWAY, NJ & FOSTER CITY, CA – June 08, 2026

In the relentless war against cancer, not all battles are won. Pharmaceutical giants Merck and Gilead Sciences delivered a sobering reminder of this fact today, announcing the discontinuation of a highly anticipated Phase 3 clinical trial. The study, known as KEYNOTE-D46/EVOKE-03, was evaluating a combination of two of the industry's most formidable oncology drugs—Merck’s immunotherapy powerhouse KEYTRUDA and Gilead’s targeted ‘smart bomb’ Trodelvy—as a first-line treatment for a specific group of patients with advanced non-small cell lung cancer (NSCLC).

The decision to halt the trial was not made lightly. It came on the recommendation of an independent Data Monitoring Committee, a neutral body of experts tasked with safeguarding patients and ensuring a trial's scientific integrity. After reviewing the data, their conclusion was stark: while the combination therapy showed a “numerical improvement” in slowing cancer progression, it failed to meet the high bar of statistical significance. More critically, it was deemed unlikely to extend patients’ overall survival, the ultimate gold standard in cancer research. For the approximately 620 patients enrolled worldwide, the news marks the end of a promising but ultimately unsuccessful avenue of investigation.

A Setback for a Population in Need

Behind the clinical terminology lies a story of human hope and scientific challenge. The trial focused on patients with metastatic NSCLC whose tumors showed high levels of a protein called PD-L1. For this group, the current standard of care is often Merck’s own KEYTRUDA, administered alone. It has proven remarkably effective, transforming the prognosis for many. The goal of the EVOKE-03 trial, therefore, was not to find a treatment, but to find a better one.

“In this specific patient population, the existing therapy is already very good, which sets an incredibly high bar for any new combination to clear,” explained an oncologist not involved in the study. “The hope was that by combining two different, powerful mechanisms of action, you could achieve a synergistic effect that would lead to deeper, more durable responses. This result is a disappointment because it means that particular one-two punch wasn't the leap forward we were looking for.”

Lung cancer remains the leading cause of cancer death globally, and the metastatic form, where the disease has spread, is particularly devastating, with a five-year survival rate below 10%. While immunotherapy has been a game-changer, it doesn’t work for everyone, and many who initially respond eventually see their disease progress. This is the tangible reality that drives the search for superior treatment strategies. The end of the EVOKE-03 trial closes one door, leaving patients and clinicians to continue relying on the established standard while hoping for breakthroughs on other fronts.

A Strategic Recalibration for Two Pharma Giants

The trial's failure represents more than just a scientific setback; it's a significant strategic event for both Merck and Gilead. For Gilead, the stakes were particularly high. The company acquired Immunomedics for $21 billion in 2020, largely to gain control of Trodelvy, a first-in-class antibody-drug conjugate (ADC). ADCs are complex therapies designed to deliver potent chemotherapy directly to cancer cells, sparing healthy tissue. A successful expansion into the massive first-line lung cancer market was a cornerstone of Gilead’s strategy to justify that investment and establish Trodelvy as a multi-billion-dollar blockbuster across different cancers.

This result forces a difficult recalibration. “The first-line NSCLC setting is the holy grail for many oncology drugs because of the large patient population,” a pharmaceutical industry analyst noted. “This failure means a significant revenue opportunity for Trodelvy is now off the table, at least in this combination and patient group. Gilead will now have to double down on its other ongoing trials in breast, bladder, and other lung cancer settings to deliver on the drug’s promise.”

For Merck, the outcome is more nuanced. While the company is always looking to expand the use of its flagship drug, KEYTRUDA, this failure ironically reinforces KEYTRUDA's strength as a standalone therapy in this very patient group. The trial was unable to prove that adding a powerful ADC could significantly improve upon what KEYTRUDA already achieves. However, it also serves as a warning for Merck's broader strategy, which relies heavily on finding successful combination partners for KEYTRUDA to extend its dominance as its patents near expiration.

The Elusive Synergy of Combination Therapy

The central question arising from the EVOKE-03 trial is a simple but profound one: why didn’t it work? The biological rationale was compelling. Trodelvy targets a protein called Trop-2, which is abundant on lung cancer cells, and delivers a payload of chemotherapy to kill them. This process, known as immunogenic cell death, was hypothesized to release tumor antigens that would act like a red flag, attracting the attention of the immune system. KEYTRUDA’s job was to then take the brakes off that immune system, allowing it to mount a more powerful attack.

However, the human body is infinitely more complex than a laboratory model. Experts suggest several potential reasons for the failure to achieve a clinically meaningful synergy. One leading theory is the “ceiling effect.” In patients with high PD-L1 expression, the immune system is already primed to attack the cancer, and KEYTRUDA is highly effective at enabling that attack. It’s possible that the benefit from KEYTRUDA alone was so substantial that the additional impact from Trodelvy was simply not enough to make a statistically significant difference.

Another possibility lies in the balance of toxicity and efficacy. While the companies reported no new safety signals, combining an ADC and an immunotherapy agent inevitably increases the side-effect burden on a patient. If the added toxicity wasn't offset by a major improvement in outcomes, the combination’s overall risk-benefit profile would be unfavorable. This outcome is a humbling lesson in the intricate dance of cancer biology, demonstrating that even two highly effective drugs may not always create a sum greater than their parts.

This result will undoubtedly inform future research. Competitors, such as AstraZeneca and Daiichi Sankyo with their own Trop-2 targeting ADC, will be watching closely, learning from this setback as they design their own combination studies. The failure underscores the critical need for better biomarkers beyond just PD-L1 to identify which patients are most likely to benefit from these complex and expensive combination therapies. The path to progress is often paved with such hard-won knowledge, and the work to find more effective strategies for patients with lung cancer continues unabated.